If a healthcare professional spends three minutes on a page, that must mean the content worked?
For years, time on page has been one of the most trusted engagement metrics in pharmaceutical marketing. It’s familiar, easy to track and simple to explain to stakeholders. When numbers go up, it feels like progress. When they go down, it signals a problem.
But in today’s digital reality, this isn’t the truth. Time on page often doesn’t mean what we think it means – and in many cases, it is actively misleading and increasingly out of step with how HCPs actually consume content online.
A metric built on a fragile assumption
Time on page is based on a single assumption: that attention is continuous and focused. The longer someone stays, the more engaged they must be. That assumption doesn’t hold up in the real world, especially not in healthcare.
Consider two very real scenarios:
One HCP opens a page, gets interrupted by a patient, answers a call, and leaves a browser tab open while attending clinical duties.
Another HCP rapidly scrolls through the content, clicks into key sections, downloads a resource and bookmarks the page to revisit later.
HCPs operate in environments defined by interruption. Consultations overrun, phones ring, clinical decisions take priority. A browser tab can stay open for minutes, even hours, without meaningful interaction.
In traditional analytics, the first HCP looks highly “engaged.” The second might barely register. Yet any marketer would agree the second interaction signals far stronger professional intent. Time on page alone can’t tell the difference.
When long time is the wrong signal
The core flaw in time on page isn’t that it’s accurate – it’s that it’s indiscriminate. It can’t tell the difference between passive presence and active interest, distraction and intent, browsing and professional evaluation.
As a result, teams can end up optimising for the wrong outcomes. Content gets rewarded for holding attention, not for delivering value. Pages are judged successful because they keep people “on site”, not because they help HCPs find what they need.
Over time, this creates a distorted view of performance, one where metrics become the goal, rather than a signal.
Why this matters more now than ever
These limitations might have been tolerable in a simpler digital landscape. But pharmaceutical marketing has changed. Today’s environment is defined by smaller, more specialised patient populations, increasingly complex scientific content, fierce competition for limited HCP attention and rising expectations from senior leadership around ROI and impact.
In this context, vague engagement signals are no longer good enough. Leadership doesn’t want reassurance that content was “viewed.” They want confidence that digital activity is driving understanding, belief and, ultimately, behaviour. A single time-based metric can’t support that level of accountability.
The quiet shift underway
This is why pharma teams are quietly moving away from time on page as a primary KPI. Some treat it as background noise. Others exclude it entirely from engagement reporting. This isn’t because engagement doesn’t matter, rather that measuring it poorly is worse than not measuring it at all.
The uncomfortable realisation is that a three-minute visit might mean nothing. A 30-second interaction might mean everything.
This leaves marketers with a critical question: if time on page is flawed, what should replace it?
To answer that, we need to redefine what good engagement actually looks like – not in theory, but in the reality of modern HCP behaviour. Read our recent whitepaper Beyond ‘time on page’ that covers this in more detail – and make sure to check out our next blog covering what good engagement looks like in 2026.
